Advertisement

pp 1-13 | Cite as

Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders

  • Stefano FiorucciEmail author
  • Cristina Di Giorgio
  • Eleonora Distrutti
Chapter
Part of the Handbook of Experimental Pharmacology book series

Abstract

Obeticholic acid (OCA), 6α-ethyl-3α,7α-dihydroxy-5-cholan-24-oic acid, is a semisynthetic derivative of the chenodeoxycholic acid (CDCA, 3α,7α-dihydroxy-5-cholan-24-oic acid), a relatively hydrophobic primary bile acid synthesized in the liver from cholesterol. OCA, also known as 6-ethyl-CDCA or INT-747, was originally described by investigators at the Perugia University in 2002 as a selective ligand for the bile acid sensor, farnesoid-X-receptor (FXR). In addition to FXR and similarly to CDCA, OCA also activates GPBAR1/TGR5, a cell membrane G protein-coupled receptor for secondary bile acids. In 2016, based on the results of phase II studies showing efficacy in reducing the plasma levels of alkaline phosphatase, a surrogate biomarker for disease progression in primary biliary cholangitis (PBC), OCA has gained approval as a second-line treatment for PBC patients nonresponsive to UDCA. The use of OCA in PBC patients associates with several side effects, the most common of which is pruritus, whose incidence is dose-dependent and is extremely high when this agent is used as a monotherapy. Additionally, the use of OCA associates with the increased risk for the development of liver failure in cirrhotic PBC patients. Currently, OCA is investigated for its potential in the treatment of nonalcoholic steatohepatitis (NASH). Phase II and III trials have shown that OCA might attenuate the severity of liver fibrosis in patients with NASH, but it has no efficacy in reversing the steatotic component of the disease, while reduces the circulating levels of HDL-C and increases LDL-C. In summary, OCA has been the first-in-class of FXR ligands advanced to a clinical stage and is now entering its third decade of life, highlighting the potential benefits and risk linked to FXR-targeted therapies.

Keywords

FXR GPBAR1 Nonalcoholic steatohepatitis (NASH) Obeticholic acid Primary biliary cholangitis (PBC) Side effects 

References

  1. Albanis E, Alvarez CE, Pruzansky M, Friedman SL, Fiorucci S (2005) INT-747, a novel FXR activator, reverses hepatic fibrosis and cirrhosis in thioacetamide-induced liver injury in rats. Hepatology 42:1040. AbsGoogle Scholar
  2. Brunt EM, Kleiner DE, Wilson LA, Sanyal AJ, Neuschwander-Tetri BA (2018) Nonalcoholic steatohepatitis clinical research network. improvements in histologic features and diagnosis associated with improvement in fibrosis in nonalcoholic steatohepatitis: results from the nonalcoholic steatohepatitis clinical research network treatment trials. Hepatology.  https://doi.org/10.1002/hep.30418
  3. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ (2001) Nuclear receptors and lipid physiology: opening the X-files. Science 294:1866–1870Google Scholar
  4. Cipriani S, Mencarelli A, Palladino G, Fiorucci S (2010) FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. Journal of Lipid Research 51:771–784Google Scholar
  5. D’Amore C, Di Leva FS, Sepe V, Renga B, Del Gaudio C, D’Auria MV, Zampella A, Fiorucci S, Limongelli V (2014) Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors. Journal of Medicinal Chemistry 57:937–954Google Scholar
  6. De Marino S, festa C, sepe V, Zampella A (2019) Chemistry and pharmacology of GPBAR1 and FXR selective agonists, dual agonists, and antagonists. In: Handbook of experimental pharmacology. Springer Nature Switzerland AG, Basel.  https://doi.org/10.1007/164_2019_237CrossRefGoogle Scholar
  7. Di Leva FS, Festa C, D’Amore C, De Marino S, Renga B, D’Auria MV, Novellino E, Limongelli V, Zampella A et al (2013) Binding mechanism of the farnesoid X receptor marine antagonist suvanine reveals a strategy to forestall drug modulation on nuclear receptors. Design, synthesis, and biological evaluation of novel ligands. Journal of Medicinal Chemistry 56:4701–4717Google Scholar
  8. Festa C, Renga B, D’Amore C, Sepe V, Finamore C, De Marino S, Carino A, Cipriani S, Monti MC et al (2014) Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands. Journal of Medicinal Chemistry 57:8477–8495Google Scholar
  9. Fiorucci S, Distrutti E (2019) Chenodeoxycholic acid: an update on its therapeutic applications. In: Handbook on experimental pharmacology. Springer, Berlin. https://doi.org/10.1007/164_2019_226
  10. Fiorucci S, Antonelli E, Rizzo G, Renga B, Mencarelli A, Riccardi L, Orlandi S, Pellicciari R, Morelli A (2004) The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127:1497–1512Google Scholar
  11. Fiorucci S, Clerici C, Antonelli E, Orlandi S, Goodwin B, Sadeghpour BM, Sabatino G, Russo G, Castellani D et al (2005a) Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. Journal of Pharmacology and Experimental Therapeutics 313:604–612Google Scholar
  12. Fiorucci S, Rizzo G, Antonelli E, Renga B, Mencarelli A, Riccardi L, Morelli A, Pruzanski M, Pellicciari R (2005b) Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. Journal of Pharmacology and Experimental Therapeutics 315:58–68Google Scholar
  13. Fiorucci S, Cipriani S, Mencarelli A, Baldelli F, Bifulco G, Zampella A (2011) Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA. Mini-Reviews in Medicinal Chemistry 11:753–762Google Scholar
  14. Fiorucci S, Distrutti E, Ricci P, Giuliano V, Donini A, Baldelli F (2014) Targeting FXR in cholestasis: hype or hope. Expert Opinion on Therapeutic Targets 18:1449–1459Google Scholar
  15. Fiorucci S, Biagioli M, Distrutti E (2018) Future trends in the treatment of non-alcoholic steatohepatitis. Pharmacol Res. 134:289–298Google Scholar
  16. Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T, Noonan DJ, Burka LT, McMorris T et al (1995) Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81:687–693Google Scholar
  17. Gao L, Lang L, Zhao X, Shay C, Shull AY, Teng Y (2018) FGF19 amplification reveals an oncogenic dependency upon autocrine FGF19/FGFR4 signaling in head and neck squamous cell carcinoma. Oncogene.  https://doi.org/10.1038/s41388-018-0591-7Google Scholar
  18. Guo L (2019) FXR agonists for the treatment of NASH and other metabolic disorders. In: Handbook on experimental pharmacology. Springer, BerlinGoogle Scholar
  19. Hameed B, Terrault NA, Gill RM, Loomba R, Chalasani N, Hoofnagle JH, Van Natta ML (2018) NASH CRN. Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics 47:645–656Google Scholar
  20. Haussinger D, Keitel V (2019) Targeting FXR in cholestasi. In: Handbook on experimental pharmacology. Springer, BerlinGoogle Scholar
  21. Hirschfield GM, Mason A, Luketic V, Lindor K, Gordon SC, Mayo M, Kowdley KV, Vincent C, Bodhenheimer HC Jr et al (2015) Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 148:751–761Google Scholar
  22. Kir S, Beddow SA, Samuel VT, Miller P, Previs SF, Suino-Powell K, Xu HE, Shulman GI, Kliewer SA et al (2011) FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331:1621–1624Google Scholar
  23. Kowdley KV, Luketic V, Chapman R, Hirschfield GM, Poupon R, Schramm C, Vincent C, Rust C, Parés A et al (2018) Obeticholic acid PBC monotherapy study group. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology 67:1890–1902Google Scholar
  24. Lang L, Teng Y (2019) Fibroblast growth factor receptor 4 targeting in cancer: new insights into mechanisms and therapeutic strategies. Cells 8:e31Google Scholar
  25. Lin ZZ, Hsu C, Jeng YM, Hu FC, Pan HW, Wu YM, Hsu HC, Cheng AL (2019) Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma. Liver Int.  https://doi.org/10.1111/liv.14055
  26. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ et al (1999) Identification of a nuclear receptor for bile acids. Science 284:1362–1365Google Scholar
  27. Maloney PR, Parks DJ, Haffner CD, Fivush AM, Chandra G, Plunket KD, Creech KL, Moore LB, Wilson JG et al (2000) Identification of a chemical tool for the orphan nuclear receptor FXR. Journal of Medicinal Chemistry 43:2971–2974Google Scholar
  28. Mencarelli A, Renga B, Distrutti E, Fiorucci S (2009a) Antiatherosclerotic effect of farnesoid X receptor. American Journal of Physiology-Heart and Circulatory Physiology 296:H272–H281Google Scholar
  29. Mencarelli A, Renga B, Migliorati M, Cipriani S, Distrutti E, Santucci L, Fiorucci S (2009b) The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. Journal of Immunology 183:6657–6666Google Scholar
  30. Moschetta A et al (2019) The intestinal enterokine fibroblast growth factor15/19 in bile acid metabolism. In: Handbook on experimental pharmacology. Springer, BerlinGoogle Scholar
  31. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P et al (2013) Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145:574–582Google Scholar
  32. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM et al (2015) NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385:956–965Google Scholar
  33. Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P et al (2016) A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. New England Journal of Medicine 375:631–643Google Scholar
  34. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM et al (1999) Bile acids: natural ligands for an orphan nuclear receptor. Science 284:1365–1368Google Scholar
  35. Pellicciari R, Fiorucci S, Camaioni E, Clerici C, Costantino G, Maloney PR, Morelli A, Parks DJ, Willson TM (2002) 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. Journal of Medicinal Chemistry 45:3569–3572Google Scholar
  36. Potthoff MJ, Boney-Montoya J, Choi M, He T, Sunny NE, Satapati S, Suino-Powell K, Xu HE, Gerard RD et al (2011) FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway. Cell Metabolism 13:729–738Google Scholar
  37. Renga B, Mencarelli A, Migliorati M, Distrutti E, Fiorucci S (2009) Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation. World Journal of Gastroenterology 15:2097–2108Google Scholar
  38. Rizzo G, Passeri D, De Franco F, Ciaccioli G, Donadio L, Rizzo G, Orlandi S, Sadeghpour B, Wang XX et al (2010) Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Molecular Pharmacology 78:617–630Google Scholar
  39. Sepe V, Distrutti E, Fiorucci S, Zampella A (2018) Farnesoid X receptor modulators 2014-present: a patent review. Expert Opinion on Therapeutic Patents 28:351–364Google Scholar
  40. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ (2000) Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102:731–744Google Scholar
  41. Vavassori P, Mencarelli A, Renga B, Distrutti E, Fiorucci S (2009) The bile acid receptor FXR is a modulator of intestinal innate immunity. Journal of Immunology 183:6251–6261Google Scholar
  42. Verbeke L, Farre R, Trebicka J, Komuta M, Roskams T, Klein S, Elst IV, Windmolders P, Vanuytsel T et al (2014) Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 59:2286–2298Google Scholar
  43. Verbeke L, Mannaerts I, Schierwagen R, Govaere O, Klein S, Vander Elst I, Windmolders P, Farre R, Wenes M, Mazzone M et al (2016) FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Scientific Reports 6:33453Google Scholar
  44. Wang H, Chen J, Hollister K, Sowers LC, Forman BM (1999) Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 3:543–553Google Scholar
  45. Zampella A (2019) Chemistry and pharmacology of GPBAR and FXR selective agonists, dual agonists and antagonists. In: Handbook on experimental pharmacology. Springer, BerlinGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Stefano Fiorucci
    • 1
    • 2
    Email author
  • Cristina Di Giorgio
    • 1
  • Eleonora Distrutti
    • 3
  1. 1.Section of Gastroenterology, Department of Surgical and Biomedical SciencesUniversity of PerugiaPerugiaItaly
  2. 2.Perugia Medical SchoolPerugiaItaly
  3. 3.Azienda Ospedaliera di PerugiaPerugiaItaly

Personalised recommendations